[ad_1] Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC Weight Watchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster…
[ad_1] There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of…
[ad_1] New research from Sweden’s Karolinska Institutet demonstrates how oestrogen protects against MASLD, a fatty liver disease that has developed rapidly during the obesity epidemic. The study, published in the journal Molecular Systems Biology, demonstrates how a new medicine under development could become a future treatment for fatty liver disease and liver cancer. Since…
[ad_1] In the realm of weight management and fostering a healthy lifestyle, subtle yet impactful modifications pave the path to success. These alterations encompass a spectrum of practices, ranging from dietary adjustments to activity integration. Embracing balanced nutrition, rich in whole foods and mindful portion control, lays the foundation. Simultaneously, incorporating physical activity into daily…
[ad_1] Pregnancy-related obesity brings with it complicated issues that demand extensive understanding and preventive care. It is critical to highlight the complex concerns that obesity in mothers poses to both the growing fetus and the expecting mother. The implications of maternal obesity extend beyond pregnancy, impacting the long-term health of both the mother and child….
[ad_1] An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated with new weight loss drugs such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound in treating obesity, there’s a very big risk printed right…
[ad_1] Sweet treats abound in today’s world, tempting our taste buds with their irresistible sweetness. However, the indulgence in these sugary delights often comes with overlooked consequences, especially for our kidney health. Our kidneys are essential for keeping us healthy. They work hard to filter waste from our blood, control blood pressure, and maintain…
[ad_1] Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to $1,500 a month — consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used…
[ad_1] Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more about how that rollout is going. One key statistic will be the number of commercial health insurers providing coverage of the drug, which was…
[ad_1] Increased sedentary time as a child through adolescence is directly linked to childhood obesity, but new research has found light physical activity may completely reverse the adverse process. According to recent reports, more than 80 per cent of adolescents across the globe do not meet the World Health Organisation’s (WHO) recommended average of 60…
